Long-term outcomes in patients treated with ADVAGRAF following standard criteria donor or expanded criteria donor kidney transplant in routine clinical practice in Europe: a multicenter secondary data (chart review) cohort study

Study identification

• EU PAS number:
  EUPAS1000000589
• Study ID:
  1000000589
• Official title and acronym:
  Long-term outcomes in patients treated with ADVAGRAF following standard criteria donor or expanded criteria donor kidney transplant in routine clinical practice in Europe: a multicenter secondary data (chart review) cohort study
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany

  Spain
• Study description:
  ADVAGRAF is a medicine used after kidney transplants to stop the immune system from rejecting the new kidney. This study will use information from clinics in Europe to learn more about the outcomes of kidney transplants treated with ADVAGRAF. This type of study is called a real-world study.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Astellas Pharma Europe Ltd.

N/A

Networks

N/A

Study timelines

Date when funding contract was signed

Actual:03/07/2024

Study start date

Actual:29/07/2025

Data analysis start date

Planned:31/07/2025

Date of final study report

Planned:30/09/2026

Sources of funding

Pharmaceutical company and other private sector 

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

506-MA-3552